Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department

NCT07726069 | Not Yet Recruiting Early Phase 1 FDA Drug

• 1 other identifier: 2026-0693
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Patients diagnosed with cannabinoid hyperemesis syndrome that are safe for discharge from the emergency department will be sent an outpatient prescription for haloperidol to be used as needed at home. The study goal is to see if having this medication available helps to prevent return emergency department visits for recurrent or persistent symptoms.

Conditions

Cannabinoid Hyperemesis Syndrome

Keywords

chs; cannabinoid hyperemesis syndrome; haldol; haloperidol

Outcome Measures

Primary Outcomes (1)

• Rate of return to the emergency department

  We plan to measure the percentage of people who return to the emergency department for recurrence of symptoms attributable to cannabinoid hyperemesis syndrome

  1 month

Secondary Outcomes (2)

• Improvement in symptoms

  1 month

• Medication side effects

  1 month

Study Arms (1)

Patients who will receive haloperidol

EXPERIMENTAL

Patients in this arm of the study will receive haloperidol to be used as needed on an outpatient basis

Drug: Haloperidol

Interventions

Haloperidol DRUG

This intervention involves providing patients an outpatient prescription for as needed haloperidol to attempt to control symptoms of cannabinoid hyperemesis and to attempt to prevent return to the emergency department for that reason.

Patients who will receive haloperidol

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients who meet ROME-4 diagnostic criteria for cannabinoid hyperemesis syndrome

You may not qualify if:

• Already on dopamine agonist/antagonist therapy for another condition Parkinson's disease Lewy body dementia Men with QTc \> 450 Women with QTc \> 460 Patients with documented allergy to haloperidol Patients with known functional prolactinomas Patients who are breastfeeding Patients under the age of 18 Patients who are pregnant Patients who are in the prison system Patients who are unable to consent

Sponsors & Collaborators

• University of Illinois at Chicago: lead

Study Sites (1)

University of Illinois Hospital

Chicago, Illinois, 60612, United States

Location

MeSH Terms

Conditions

Cannabinoid Hyperemesis Syndrome; Chediak-Higashi Syndrome

Interventions

Haloperidol

Condition Hierarchy (Ancestors)

Marijuana Abuse; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders; Albinism; Eye Diseases, Hereditary; Eye Diseases; Phagocyte Bactericidal Dysfunction; Leukocyte Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Primary Immunodeficiency Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Immunologic Deficiency Syndromes; Immune System Diseases

Intervention Hierarchy (Ancestors)

Butyrophenones; Ketones; Organic Chemicals

Study Officials

• Wesley Eilbert, MD

  University of Illinois Health

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Mason A Bartman, MD

CONTACT

8178972205; mbartman@uic.edu

Wesley Eilbert, MD

CONTACT

6302944225; weilbert@uic.edu

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: July 21, 2026
• First Posted: July 24, 2026
• Study Start (Estimated): November 1, 2026
• Primary Completion (Estimated): January 1, 2028
• Study Completion (Estimated): January 1, 2028
• Last Updated: July 24, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)